Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
ATC Code
S01AE08
Source
TFDA
USFDA:Besifloxacin
S01AE08(WHO)
US:℞-only
7-[(3R)-3-Aminoazepam-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
141388-76-3
10178705
8354210
BFE2NBZ7NX
ChEMBL1201760
DTXSID00161706
Interactive image
Fc1c(c(Cl)c2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N4CCCC[C@@H](N)C4
InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1Key:QFFGVLORLPOAEC-SNVBAGLBSA-N
Besifloxacin(INN/USAN) is a fourth-generationfluoroquinoloneantibiotic. The marketed compound is besifloxacinhydrochloride.
It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 forophthalmic useto InSite Vision Incorporated (OTC Pink:INSV) in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights toBausch & Lombin 2003.
The eye drop was approved by the United States Food and Drug Administration (FDA) on May 29, 2009, and marketed under the trade nameBesivance.
⚠️ Warnings
• Caution should be exercised in people who are using contact lenses, during pregnancy and breastfeeding.
• It may cause blurred vision, do not drive a car or operate machinery while taking this medication.
• Avoid long-term use of this medication; otherwise it may cause secondary infection.
